LFMD

LifeMD, Inc. (LFMD) | Rumor.io

LifeMD

LFMD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,631

Bullish sentiment (50-day avg)74%

Price to earnings ratio11.7

Market capitalization141.2M

Earnings per share-0.53

Dividend yield (TTM)—

Revenue (annual)194.1M

Net income (annual)15.6M

Social

What share of all stock conversation is about LFMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Jul 8

Federated Hermes has significantly increased its holdings in LifeMD, Inc. (LFMD), owning 5.68% of the company after a 170% increase.
LFMD's price is currently at $4.88, and some investors are considering cutting losses, while others are looking to buy the dip.
LifeMD's price has been declining, and some users are speculating about its potential bottoming out or the possibility of deeper issues, but no concrete conclusions are drawn.

Generated by AI

Sentiment

Of the messages about LFMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	78.57% +9.52	75.26% +11.7
Bearish	—	—	21.43% -9.52	24.74% -11.7

Bullish· Mar 16

The company has made a positive change in management with the appointment of a new CFO, which has led to a stock price increase of 7% pre-market.
Mizuho has upgraded the stock to Outperform from Neutral and raised its price target to $8, indicating a positive outlook for the company's growth.
The company's new position CBO is expected to focus on B2B, which could be a significant revenue driver and has not been fully priced into the stock, making it a potential opportunity for investors.

Bearish· Aug 6

$LFMD's Q2 results were a "good quarter, bad guide" with adjusted EBITDA up 223% and a debt-free status, but full-year revenue guidance was slashed from $272M to $253M.
The company's subscription price was too high, and adjusted EBITDA was over-stating profits, which led to a bearish outlook despite the CEO and CFO's efforts to convince otherwise.
$LFMD's management has been criticized for not handling hiccups properly and not relaying information effectively to shareholders, which has led to issues with the stock's performance.

Generated by AI

Topics

Of the messages about LFMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	83.33%	10.97%
Technical Analysis	—	—	11.11%	2.72%
Earnings	—	—	2.78%	4.37%
Analysts	—	—	2.78%	40.67%
Controversies	—	—	0%	0.3%
Macro	—	—	0%	40.97%

Earnings· Aug 6

LifeMD, Inc. ($LFMD) reported disappointing Q2 earnings, with revenue missing estimates by $4.09M and adjusted EBITDA guidance cut by ~12.5%.
The company's full-year revenue guidance was lowered by ~7% to $253M, with telehealth adjusted EBITDA guidance cut by ~29%.
Despite a good quarter in terms of adjusted EBITDA and operating cash flow, the stock price dropped by over 40% due to the guidance cut and concerns about the company's ability to predict its business.

Announcements· Mar 16

LifeMD, Inc. ($LFMD) has appointed Atul Kavthekar as Chief Financial Officer, effective immediately, succeeding Marc Benathen.
The appointment has been met with a positive market reaction, with the stock opening 17% higher.
Mizuho has upgraded LifeMD to Outperform from Neutral and raised its price target from $6 to a new undisclosed amount.

Generated by AI

Community

Of the messages about LFMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.11%	48.27%
Newcomers	—	—	26.89%	51.73%

Regulars· Nov 18

LifeMD's Q3 earnings were a double miss, and the company lowered its guidance, causing the stock to plummet.
Despite the drop, regulars believe LifeMD is extremely undervalued and has potential for growth.
The company's partnerships with Novo and Lilly are being threatened by low-cost GLP-1 weight loss drugs, which may impact LifeMD's sales.

Newcomers· Mar 16

LifeMD's stock price increased due to the appointment of Atul Kavthekar as CFO, replacing Marc Benathen.
Mizuho upgraded LifeMD's shares from 'Neutral' to 'Outperform' with a higher price target of $8, up from $6.
Atul Kavthekar's CFO appointment is seen as a positive development for LifeMD's future.

Generated by AI

LifeMD, Inc. (NASDAQ:LFMD) announced an exclusive healthcare collaboration on September 15 that initially makes virtual-health membership benefits available to approximately 29 million eligible AT&T wireless and fiber customers across 11 states. Customers must be 18 or older, and some services have additional eligibility and state restrictions. A nationwide expansion planned for January 2027 would extend […]

9d agoYahoo Finance

AT&T launches free healthcare perk for customers

11d agothestreet.com

H.C. Wainwright reiterates LifeMD stock rating on AT&T deal

11d agoInvesting.com

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

13d agoYahoo Finance

LifeMD: Still Undervalued Despite Earnings Miss (NASDAQ:LFMD)

13d agoSeeking Alpha

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

Detailed price information for AT&T Inc (T-N) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Also Discussed

Investors talking about LFMD also mention

#	Name	Attention
1	Hims & Hers Health, Inc.HIMS	0.17%+0.1
2	Real Brokerage Inc.REAX	0%+0
3	Sezzle Inc.SEZL	0%+0
4	TransMedics Group, Inc.TMDX	0%-0.01
5	Zeta Global Holdings Corp.ZETA	0%-0.03
6	Leverage Shares 2x Long CRML Daily ETFCRMU	0%0
7	Kaspi.kz JSC ADRKSPI	0%-0.01
8	Oddity Tech Ltd. Class A Ordinary SharesODD	0%new
9	UFP Technologies Inc.UFPT	0%0
10	ATHN - Athena Technology Acquisition Corp.	——

LifeMD, Inc.

Healthcare
Health Information Services

LifeMD, Inc. is a direct-to-patient telehealth company that provides virtual medical care and pharmacy services across the United States. LifeMD’s platform connects patients with licensed healthcare providers for primary care, urgent care, and chronic care management, supported by digital prescribing, lab testing, and care coordination tools. The company also offers specialized consumer health brands focused on men’s health, hair loss, women’s health, allergy and asthma care, and other common conditions, along with related prescription and over-the-counter products. In addition, LifeMD serves patients through subscription and membership-based care models designed to make access to healthcare more convenient and streamlined. Headquartered in New York, LifeMD operates at the intersection of telehealth, pharmacy fulfillment, and digital healthcare services.

Website

Location

236 Fifth Avenue

New York, NY, 10001

United States

Social

What share of all stock conversation is about LFMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Jul 8

Federated Hermes has significantly increased its holdings in LifeMD, Inc. (LFMD), owning 5.68% of the company after a 170% increase.
LFMD's price is currently at $4.88, and some investors are considering cutting losses, while others are looking to buy the dip.
LifeMD's price has been declining, and some users are speculating about its potential bottoming out or the possibility of deeper issues, but no concrete conclusions are drawn.

Generated by AI

Sentiment

Of the messages about LFMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	78.57% +9.52	75.26% +11.7
Bearish	—	—	21.43% -9.52	24.74% -11.7

Bullish· Mar 16

The company has made a positive change in management with the appointment of a new CFO, which has led to a stock price increase of 7% pre-market.
Mizuho has upgraded the stock to Outperform from Neutral and raised its price target to $8, indicating a positive outlook for the company's growth.
The company's new position CBO is expected to focus on B2B, which could be a significant revenue driver and has not been fully priced into the stock, making it a potential opportunity for investors.

Bearish· Aug 6

$LFMD's Q2 results were a "good quarter, bad guide" with adjusted EBITDA up 223% and a debt-free status, but full-year revenue guidance was slashed from $272M to $253M.
The company's subscription price was too high, and adjusted EBITDA was over-stating profits, which led to a bearish outlook despite the CEO and CFO's efforts to convince otherwise.
$LFMD's management has been criticized for not handling hiccups properly and not relaying information effectively to shareholders, which has led to issues with the stock's performance.

Generated by AI

Topics

Of the messages about LFMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	83.33%	10.97%
Technical Analysis	—	—	11.11%	2.72%
Earnings	—	—	2.78%	4.37%
Analysts	—	—	2.78%	40.67%
Controversies	—	—	0%	0.3%
Macro	—	—	0%	40.97%

Earnings· Aug 6

LifeMD, Inc. ($LFMD) reported disappointing Q2 earnings, with revenue missing estimates by $4.09M and adjusted EBITDA guidance cut by ~12.5%.
The company's full-year revenue guidance was lowered by ~7% to $253M, with telehealth adjusted EBITDA guidance cut by ~29%.
Despite a good quarter in terms of adjusted EBITDA and operating cash flow, the stock price dropped by over 40% due to the guidance cut and concerns about the company's ability to predict its business.

Announcements· Mar 16

LifeMD, Inc. ($LFMD) has appointed Atul Kavthekar as Chief Financial Officer, effective immediately, succeeding Marc Benathen.
The appointment has been met with a positive market reaction, with the stock opening 17% higher.
Mizuho has upgraded LifeMD to Outperform from Neutral and raised its price target from $6 to a new undisclosed amount.

Generated by AI

Community

Of the messages about LFMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.11%	48.27%
Newcomers	—	—	26.89%	51.73%

Regulars· Nov 18

LifeMD's Q3 earnings were a double miss, and the company lowered its guidance, causing the stock to plummet.
Despite the drop, regulars believe LifeMD is extremely undervalued and has potential for growth.
The company's partnerships with Novo and Lilly are being threatened by low-cost GLP-1 weight loss drugs, which may impact LifeMD's sales.

Newcomers· Mar 16

LifeMD's stock price increased due to the appointment of Atul Kavthekar as CFO, replacing Marc Benathen.
Mizuho upgraded LifeMD's shares from 'Neutral' to 'Outperform' with a higher price target of $8, up from $6.
Atul Kavthekar's CFO appointment is seen as a positive development for LifeMD's future.

Generated by AI

LifeMD

Social

Jul 8

Bullish· Mar 16

Bearish· Aug 6

Earnings· Aug 6

Announcements· Mar 16

Regulars· Nov 18

Newcomers· Mar 16

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

AT&T launches free healthcare perk for customers

H.C. Wainwright reiterates LifeMD stock rating on AT&T deal

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

LifeMD: Still Undervalued Despite Earnings Miss (NASDAQ:LFMD)

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

Also Discussed

LifeMD, Inc.

Company Information

Location

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

AT&T launches free healthcare perk for customers

H.C. Wainwright reiterates LifeMD stock rating on AT&T deal

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

LifeMD: Still Undervalued Despite Earnings Miss (NASDAQ:LFMD)

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

Also Discussed

Social

Jul 8

Bullish· Mar 16

Bearish· Aug 6

Earnings· Aug 6

Announcements· Mar 16

Regulars· Nov 18

Newcomers· Mar 16